News & Events zu Prokidney Corp (PROK)PROKProkidney Corp

ProKidney Reports Q2 Revenue of $150K, Cash Reserves of $181.6M

Reports Q2 revenue $150K, consensus $149K. Ended Q2 with $181.6M in cash, cash equivalents, and marketable securities, which the company expects to support operations into mid-2027. The company completed patient enrollment for the Phase 3 PROACT 1 accelerated approval efficacy analysis, with pivotal topline results anticipated in Q2 2027. "This update marks an important milestone for ProKidney as we have completed enrollment for the PROACT 1 accelerated approval analysis, positioning us for our pivotal eGFR slope topline readout anticipated in the second quarter of 2027," said Bruce Culleton, CEO of ProKidney.

ProKidney Appoints Kenneth Locke as Chief Technical Officer

ProKidney (PROK) announced the appointment of Kenneth Locke as chief technical officer. Locke joins ProKidney from Carisma Therapeutics (CARM), where he oversaw CMC, Quality and Regulatory functions and led technical strategy for first-in-human CAR Myeloid programs.

ProKidney Reports Q1 Revenue of $226,000

Reports Q1 revenue $226,000, consensus $100,250."As we progress through 2026, we continue to build on the momentum established last year through positive Phase 2 REGEN-007 results, alignment with the FDA on the accelerated approval pathway, and meaningful progress on Phase 3 PROACT 1 study enrollment," said Bruce Culleton, M.D., CEO of ProKidney. "We expect to complete enrollment in PROACT 1 this year, positioning us to deliver pivotal eGFR slope topline results in the second quarter of 2027. Our mission remains highly focused on advancing a potential new treatment option for patients with advanced CKD and diabetes at high risk of kidney failure, an area of significant unmet medical need."